Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. The company reported quarterly sales of $2.181 million which beat the analyst consensus estimate of $800.000 thousand by 172.63 percent. This is a 223.11 percent increase over sales of $675.000 thousand the same period last year.
Vaxart Q1 2024 GAAP EPS $(0.14), Inline, Sales $2.181M Beat $800.000K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.